ClinicalTrials.gg
TerminatedNCT03699202ASCENTUpdated Jun 22, 2026

Anti-RSV Study in Chinese Patients (ASCENT)

A Phase 2 interventional study of AK0529 and Placebo in Respiratory Syncytial Virus Infections, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Terminated at 22 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated early due to COVID-19-related enrollment disruptions, not as a result of any product safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Respiratory Syncytial Virus Infections with a site in China — 8 open to participants now, 13 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · China.

Enrollment
25th of 25
1 · median 132
Started
2019
the only one that year
Phase 2
6 of 30
1 open now
Registered
1st of 30
by date
Lead sponsor
4 of 30
Shanghai Ark Biopharmaceutical Co., Ltd.

Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, this one is the 25th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2019, is one of 6 in phase 2, and was the 1st registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

8 of the 30 studies in Respiratory Syncytial Virus Infections with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Respiratory Syncytial Virus Infections with a site in China, or all of them as a file.
02

Study summary

This is a randomised, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered AK0529 in Chinese adults with RSV infection.

Read the detailed description

This is a randomised, double-blind, placebo-controlled, multicentre, phase 2 study in Chinese adult outpatients with RSV infection. Approximately 160 eligible patients who have been recently diagnosed with RSV infection are planned to be enrolled into the study. Symptom scores of patients before and after treatment will be evaluated. Meanwhile, nasopharyngeal samples and blood samples will be collected for virological and pharmacokinetics evaluations. The evaluation of the safety and tolerability will include AE/SAE, vital signs, physical examination, laboratory examination and 12-lead ECGs. The total study duration for each patient will be 20 days.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • RSV,AK0529,Chinese
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 - 75 years, inclusive.
  • Confirmed with RSV infection by rapid diagnostic testing.
  • New onset with documentation of the following symptoms within 72 hours prior to the start of screening: Respiratory symptoms: runny nose, stuffy nose, sneezing, sore throat, earache, cough, shortness of breath; Systemic symptoms: headache, fatigue / lethargy, fever, and muscle and / or joint ache. The patient must have four symptoms of above, and at least one of these must be respiratory symptom in nature.
  • Able and willing to provide written and to comply with the study protocol.

Exclusion criteria

Exclusion Criteria:

  • The patient has taken, is taking or needs to take any antiviral medication (e.g. ribavirin, Chinese medicine or herbs with effects of treating respiratory tract infection) within the 72 hours prior to screening.
  • Awareness of concomitant infections of respiratory viruses (eg, influenza A, B), bacterial or fungal infections, including systemic bacterial or fungal infections within 7 days prior to screening or during the screening period.
  • Patient frailty was evaluated as "Vulnerable" or worse according to the Clinical Frailty Scale with a score ≥ 4 at screening.
  • Awareness of having positive results on or antibody or (HIV 1 or HIV 2).
  • Patient with active tuberculosis or is taking antituberculosis treatment.
  • Patient with severe gastrointestinal disease which could impact drug absorption, eg, vomiting, malabsorption syndrome, or short bowel syndrome caused by necrotizing enterocolitis.
  • Patient with any congenital heart disease, acute or chronic heart failure, ischemic heart disease, or congenital long syndrome, or any clinical manifestation resulting in QT interval prolongation.
  • Patient with malignant tumor.
  • Patient has received or is waiting for bone marrow, stem cell or solid organ transplantation.
  • Patient with any immune-related disease to be treated within 12 months prior to screening.
  • Patient with clinical laboratoy test values of ≥ 2x the (ULN) for or aspartate aminotransferase, or >1x ULN for total , or >1.5xULN for serum creatinine.
  • Patient with electrolyte disorders, eg, hypokalemia, hypocalcemia, or hypomagnesemia.
  • Patient with history of drug or alcohol abuse within 12 months prior to screening ("alcohol abuse" definition is >14 units per week: 1 unit = 10mL Alcohol, or 250mL of 4% beer, or 25 mL of 40% spirit, or 75 mL of 13% wine).
  • Patient has allergy or to study medication or its compositions.
  • Female patient with positive pregnancy test result or is lactating.
  • Patient with fertility refusing to use medically effective during the study or within three months of the end of study.
  • Patient participated in an drug or device study within 60 days prior to screening.
  • Patient who in the opinion of the investigator, is deemed as ineligible for the study, including patients who are with active psychiatric disease, or are taking psychiatric medication.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    100mg AK0529 Arm

    Patients randomised into this arm will be orally administered with 100mg AK0529 q.d. for five days.

    Drug: AK0529

  • Experimental
    200mg AK0529 Arm

    Patients randomised into this arm will be orally administered with 200mg AK0529 q.d. for five days.

    Drug: AK0529

  • Experimental
    300mg AK0529 Arm

    Patients randomised into this arm will be orally administered with 300mg AK0529 q.d. for five days.

    Drug: AK0529

  • Placebo comparator
    Placebo Arm

    Patients randomised into this arm will be orally administered with placebo q.d. for five days.

    Drug: Placebo

Interventions

  • DrugAK0529

    AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.

    Also known as: Ziresovir

  • DrugPlacebo

    The placebo is made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed of microcrystaline cellulose pellet.

06

What researchers measure

Primary outcomes

  1. Change of symptom score

    To evaluate the change of patient-reported symptom score in AK0529 arms compared with the change in placebo arm after treatment. The scale is Wang bronchiolitis score and the total score is reported with a range from 0 to 12. A decreasing value of total score represents clinical improvement. Subscales are not applicable in this symptom score.

    Time frame: From Day 0 to Day 5

  2. Incidence of adverse events during the study

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: From Day -3 to Day 14

  3. Subject withdrawals due to treatment-emergent adverse events

    A treatment-emergent adverse event (TEAE) is an AE that first appears during treatment, which was absent before or which worsens relative to the pre-treatment state.

    Time frame: From Day -3 to Day 14

Secondary outcomes

  1. Area under curve change of viral load

    The antiviral effects in adults with RSV infection are to be determined by measuring the RSV viral load area under the curve from baseline to last administration of study medication .

    Time frame: From Day 0 to Day 5

07

Study locations

22 sites
  • Beijing Ditan Hospital
    Beijing, Beijing Municipality 100015, China
  • Beijing Anzhen Hospital
    Beijing, Beijing Municipality 100029, China
  • Quanzhou First Hospital
    Quanzhou, Fujian 362000, China
  • Huizhou Municipal Central Hospital
    Huizhou, Guangdong 516001, China
  • The Second Affiliated Hospital of Hainan Medical University
    Haikou, Hainan 571199, China
  • Sanya Central Hospital
    Sanya, Hainan 572000, China
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
  • Nanjing First Hospital
    Nanjing, Jiangsu 210006, China
  • Jiangsu Taizhou People's Hospital
    Taizhou, Jiangsu 225300, China
  • Qingdao Municipal Hospital
    Qingdao, Shandong 266011, China
  • People's Hospital of Deyang City
    Deyang, Sichuan 618000, China
  • Suining Central Hopital
    Suining, Sichuan 629000, China
  • China-Japan Friendship Hospital
    Beijing, 100029, China
  • Beijing Pinggu Hospital
    Beijing, 101200, China
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, 233004, China
  • Nantong First People's Hospital
    Nantong, 226001, China
  • Shanghai East Hospital
    Shanghai, 200120, China
  • Central Hospital of Minhang District, Shanghai
    Shanghai, 201199, China
  • Shenzhen People's Hospital
    Shenzhen, 518001, China
  • Xiangtan Central Hospital
    Xiangtan, 411100, China
  • Xinxiang First People's Hospital
    Xinxiang, 453000, China
  • Affiliated Hospital of Zunyi Medical University
    Zunyi, 563000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Apr 2019, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2018
First posted
Oct 9, 2018
StartActual
Mar 28, 2019
Primary completionActual
Apr 4, 2019
CompletionActual
Apr 4, 2019
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03699202
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Oct 9, 2018
Start date
Mar 28, 2019
Primary completion
Apr 4, 2019
Completion
Apr 4, 2019
Last update
Jun 22, 2026

Study contacts

Ark Clinical Trial
study director · info@arkbiosciences.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziresovir

Start the discussion